DDInter1763 DDInter1085
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R).
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Lomitapide
Temsirolimus {u} (Compound) causes {v} (Side Effect) Dry skin
Dry skin {u} (Side Effect) is caused by {v} (Compound) Lomitapide
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomitapide
Temsirolimus {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Conivaptan
Conivaptan {u} (Compound) resembles {v} (Compound) Lomitapide
Temsirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Apixaban
Apixaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomitapide
Temsirolimus {u} (Compound) causes {v} (Side Effect) Dry skin
Dry skin {u} (Side Effect) is caused by {v} (Compound) Paclitaxel
Paclitaxel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomitapide
Temsirolimus {u} (Compound) causes {v} (Side Effect) Vomiting
Vomiting {u} (Side Effect) is caused by {v} (Compound) Conivaptan
Conivaptan {u} (Compound) resembles {v} (Compound) Lomitapide
Temsirolimus {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Antrafenine
Antrafenine {u} (Compound) resembles {v} (Compound) Lomitapide
Temsirolimus {u} (Compound) resembles {v} (Compound) Sirolimus
Sirolimus {u} may lead to a major life threatening interaction when taken with {v} Conivaptan
Conivaptan {u} (Compound) resembles {v} (Compound) Lomitapide
Temsirolimus {u} (Compound) causes {v} (Side Effect) Dermatitis bullous
Dermatitis bullous {u} (Side Effect) is caused by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lomitapide
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lomitapide (Compound)
Temsirolimus (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Lomitapide (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Temsirolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Conivaptan (Compound) and Conivaptan (Compound) resembles Lomitapide (Compound)
Temsirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Apixaban (Compound) and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Temsirolimus (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Paclitaxel (Compound) and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide
Temsirolimus (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Conivaptan (Compound) and Conivaptan (Compound) resembles Lomitapide (Compound)
Temsirolimus (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Antrafenine (Compound) and Antrafenine (Compound) resembles Lomitapide (Compound)
Temsirolimus (Compound) resembles Sirolimus (Compound) and Sirolimus may lead to a major life threatening interaction when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Temsirolimus (Compound) causes Dermatitis bullous (Side Effect) and Dermatitis bullous (Side Effect) is caused by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Lomitapide